305 related articles for article (PubMed ID: 30930440)
41. A novel approach for predicting the dissolution profiles of pharmaceutical tablets.
Paus R; Hart E; Ji Y
Eur J Pharm Biopharm; 2015 Oct; 96():53-64. PubMed ID: 26170163
[TBL] [Abstract][Full Text] [Related]
42. Delay effect of magnesium stearate on tablet dissolution in acidic medium.
Ariyasu A; Hattori Y; Otsuka M
Int J Pharm; 2016 Sep; 511(2):757-64. PubMed ID: 27444551
[TBL] [Abstract][Full Text] [Related]
43. Evaluation of in vitro dissolution profiles of modified-release metoprolol succinate tablets crushed using mortar and pestle technique.
Kir F; Al-Sulaiti FK; Sahin S
Eur J Pharm Sci; 2024 Mar; 194():106694. PubMed ID: 38191064
[TBL] [Abstract][Full Text] [Related]
44. Prediction of drug dissolution from Toremifene 80 mg tablets by NIR spectroscopy.
Ojala K; Myrskyranta M; Liimatainen A; Kortejärvi H; Juppo A
Int J Pharm; 2020 Mar; 577():119028. PubMed ID: 31954865
[TBL] [Abstract][Full Text] [Related]
45. Assessment of NIR spectroscopy for nondestructive analysis of physical and chemical attributes of sulfamethazine bolus dosage forms.
Tatavarti AS; Fahmy R; Wu H; Hussain AS; Marnane W; Bensley D; Hollenbeck G; Hoag SW
AAPS PharmSciTech; 2005 Sep; 6(1):E91-9. PubMed ID: 16353969
[TBL] [Abstract][Full Text] [Related]
46. Incompatibility of croscarmellose sodium with alkaline excipients in a tablet formulation.
Bindra DS; Stein D; Pandey P; Barbour N
Pharm Dev Technol; 2014 May; 19(3):285-9. PubMed ID: 23528069
[TBL] [Abstract][Full Text] [Related]
47. Effects of lubricant-mixing time on prolongation of dissolution time and its prediction by measuring near infrared spectra from tablets.
Abe H; Otsuka M
Drug Dev Ind Pharm; 2012 Apr; 38(4):412-9. PubMed ID: 21954869
[TBL] [Abstract][Full Text] [Related]
48. Development of Tablet Formulation of Amorphous Solid Dispersions Prepared by Hot Melt Extrusion Using Quality by Design Approach.
Agrawal A; Dudhedia M; Deng W; Shepard K; Zhong L; Povilaitis E; Zimny E
AAPS PharmSciTech; 2016 Feb; 17(1):214-32. PubMed ID: 26757898
[TBL] [Abstract][Full Text] [Related]
49. Matrix tablets based on a carrageenan with the modified-release of sodium riboflavin 5'-phosphate.
Buchholcz G; Kelemen A; Sovány T; Pintye-Hódi K
Pharm Dev Technol; 2015; 20(6):676-83. PubMed ID: 24758384
[TBL] [Abstract][Full Text] [Related]
50. Effects of tablet formulation and subsequent film coating on the supersaturated dissolution behavior of amorphous solid dispersions.
Sakai T; Hirai D; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 540(1-2):171-177. PubMed ID: 29447848
[TBL] [Abstract][Full Text] [Related]
51. Quality-by-design case study: investigation of the role of poloxamer in immediate-release tablets by experimental design and multivariate data analysis.
Kaul G; Huang J; Chatlapalli R; Ghosh K; Nagi A
AAPS PharmSciTech; 2011 Dec; 12(4):1064-76. PubMed ID: 21861241
[TBL] [Abstract][Full Text] [Related]
52. Influence of drug load on dissolution behavior of tablets containing a poorly water-soluble drug: estimation of the percolation threshold.
Wenzel T; Stillhart C; Kleinebudde P; Szepes A
Drug Dev Ind Pharm; 2017 Aug; 43(8):1265-1275. PubMed ID: 28398095
[TBL] [Abstract][Full Text] [Related]
53. Design and evaluation of sustained release bilayer tablets of propranolol hydrochloride.
Patra CN; Kumar AB; Pandit HK; Singh SP; Devi MV
Acta Pharm; 2007 Dec; 57(4):479-89. PubMed ID: 18165191
[TBL] [Abstract][Full Text] [Related]
54. Influence of in vitro test conditions on release of aspirin from commercial tablets.
Nikolić L; Djurić Z; Jovanović M
J Pharm Sci; 1992 Apr; 81(4):386-91. PubMed ID: 1501078
[TBL] [Abstract][Full Text] [Related]
55. UV/Vis spectroscopy as an in-line monitoring tool for tablet content uniformity.
Brands R; Tebart N; Thommes M; Bartsch J
J Pharm Biomed Anal; 2023 Nov; 236():115721. PubMed ID: 37769525
[TBL] [Abstract][Full Text] [Related]
56. A comparative study of the dissolution characteristics of capsule and tablet dosage forms of melt granulations of paracetamol--diluent effects.
Uhumwangho MU; Okor RS
Acta Pol Pharm; 2007; 64(1):73-9. PubMed ID: 17665854
[TBL] [Abstract][Full Text] [Related]
57. Application of artificial neural networks for Process Analytical Technology-based dissolution testing.
Nagy B; Petra D; Galata DL; Démuth B; Borbás E; Marosi G; Nagy ZK; Farkas A
Int J Pharm; 2019 Aug; 567():118464. PubMed ID: 31252145
[TBL] [Abstract][Full Text] [Related]
58. Understanding the impact of media viscosity on dissolution of a highly water soluble drug within a USP 2 mini vessel dissolution apparatus using an optical planar induced fluorescence (PLIF) method.
Stamatopoulos K; Batchelor HK; Alberini F; Ramsay J; Simmons MJH
Int J Pharm; 2015 Nov; 495(1):362-373. PubMed ID: 26363111
[TBL] [Abstract][Full Text] [Related]
59. Effect of lipid and cellulose based matrix former on the release of highly soluble drug from extruded/spheronized, sintered and compacted pellets.
Maboos M; Yousuf RI; Shoaib MH; Nasiri I; Hussain T; Ahmed HF; Iffat W
Lipids Health Dis; 2018 Jun; 17(1):136. PubMed ID: 29885655
[TBL] [Abstract][Full Text] [Related]
60. Prediction of Dissolution Profiles From Process Parameters, Formulation, and Spectroscopic Measurements.
Zhao Y; Li W; Shi Z; Drennen JK; Anderson CA
J Pharm Sci; 2019 Jun; 108(6):2119-2127. PubMed ID: 30742835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
